Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of RO5024048 + telaprevir + Pegasys + Copegus in prior null responders with chronic hepatitis C genotype 1
2011-002715-28Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mericitabine in chronic hepatitis C virus infection (3 arms), sponsored by Roche. Primary endpoint: Sustained virologic response at 12 weeks post-treatment (SVR-12). Started Sep 2011; status: completed.
02
Drugs
mericitabine
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on 2011-002715-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002715-28.